MingSight-Relin Pharmaceuticals Co., Ltd. Report issue

For profit Phase 2
Founded: China (2011)

Organization Overview

First Clinical Trial
2020
NCT04187443
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

ms-553 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetic Retinopathy (Phase 1)

Edema (Phase 1)

Macular Edema (Phase 1)

Retinal Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1